Growth Metrics

Capricor Therapeutics (CAPR) EBT (2016 - 2025)

Historic EBT for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.

  • Capricor Therapeutics' EBT fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 10498.83%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
  • As of Q3 2025, Capricor Therapeutics' EBT stood at -$24.6 million, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' EBT peaked at -$829093.0 during Q4 2023, and registered a low of -$25.9 million during Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' median EBT value was -$7.2 million (recorded in 2023), while the average stood at -$9.3 million.
  • Per our database at Business Quant, Capricor Therapeutics' EBT soared by 8921.39% in 2023 and then tumbled by 74565.53% in 2024.
  • Quarter analysis of 5 years shows Capricor Therapeutics' EBT stood at -$6.4 million in 2021, then fell by 20.79% to -$7.7 million in 2022, then skyrocketed by 89.21% to -$829093.0 in 2023, then tumbled by 745.66% to -$7.0 million in 2024, then tumbled by 250.44% to -$24.6 million in 2025.
  • Its EBT was -$24.6 million in Q3 2025, compared to -$25.9 million in Q2 2025 and -$7.0 million in Q4 2024.